{"url_path":"/sec/cntx/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1842952/0001628280-26-035793-index.html","accession_number":"0001628280-26-035793","cik":"0001842952","ticker":"CNTX","issuer_name":"Context Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1842952/0001628280-26-035793-index.html","primary_entity_key":"0001842952","primary_entity_name":"Context Therapeutics Inc."},"word_count":129,"has_tables":true,"body_markdown":"Item 9.01. Exhibits.\n\n(d) Exhibits\n\nExhibit No.    Description\n\n10.1#    [First Amendment to License Agreement, dated May](exhibit101bioatla-contexta.htm)[14](exhibit101bioatla-contexta.htm)[, 2026, by and between the Company and BioAtla, Inc.](exhibit101bioatla-contexta.htm)\n\n99.1    [Press Release issued by Context Therapeutics Inc., dated May](exhibit99105182026bioatlal.htm)[18](exhibit99105182026bioatlal.htm)[, 2026](exhibit99105182026bioatlal.htm)\n\n104    Cover Page Interactive Data File (embedded within the inline XBRL document)\n\n# Certain schedules to this agreement have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedules will be furnished supplementally to the SEC upon request.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDated: May 18, 2026Context Therapeutics Inc.\n\nBy: /s/ Martin A. Lehr\n\nName: Martin A. Lehr\n\nTitle: Chief Executive Officer"}